FTY720 (fingolimod) for relapsing multiple sclerosis

  title={FTY720 (fingolimod) for relapsing multiple sclerosis},
  author={Alejandro Horga and Xavier Montalban},
  journal={Expert Review of Neurotherapeutics},
  pages={699 - 714}
FTY720 (fingolimod) is a structural analogue of sphingosine, an endogenous lysophospholipid, which targets sphingosine-1-phosphate receptors after biotransformation to FTY720-phosphate. The immunomodulatory properties of this agent are mainly related to its ability to entrap lymphocytes in secondary lymphoid organs, reducing their availability for cell-mediated immune responses. Emerging evidence suggests that FTY720 also exerts direct actions on glial and precursor cells of the CNS which may… 

Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis

Fingolimod reduces relapses more effectively than intramuscular interferon β1a and delays disability progression and may target not only inflammation but potentially also neurodegeneration.

Fingolimod for relapsing multiple sclerosis: an update

Importance of the field: Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the CNS. There is a large unmet need for new disease-modifying therapies with improved

Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis

The case of a 34-year-old male with relapsing-remitting multiple sclerosis, who developed acute anterior uveitis on day 5 of fingolimod treatment, is reported.

A Computational Investigation of FTY720P-Mediated Neuroprotection in Multiple Sclerosis

This investigation used a qualitative systems biology approach and the computer modeling tool, CellDesigner, to create computational signaling models of the S1P receptors and of cell types that are involved in the observed FTY720P-mediated neuroprotection in MS.

Modulators of the Sphingosine 1-phosphate receptor 1.

Emerging multiple sclerosis oral therapies

Fingolimod, a novel immunosuppressant, significantly lowered annual relapse rates in phase II/III trials and teriflunomide, an immunomodulator, significantly reduced MRI lesion activity and reduced annual relapse Rates in a phase II trial.

Management of disease‐modifying treatments in neurological autoimmune diseases of the central nervous system

Approaches for individiualized risk–benefit assessment both for newly introduced agents as well as medications with established side‐effect profiles are discussed, and clinical parameters, including biomarkers that may assist in patient selection are focused on.

The Role of MicroRNAs in Repair Processes in Multiple Sclerosis

The role of miRNAs in remyelination in the different cell types that contribute to MS is examined, focusing on key miRNA that have a central role in mediating the repair process, along with several more that play either secondary or inhibitory roles in one or more aspects.

Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary

More than a dozen substances are meanwhile available for the disease-modifying immunotherapy of multiple sclerosis (MS). However, for some substances, there is a clear difference between approval in



FTY720 (fingolimod) in renal transplantation

FTY is highly effective in prolonging allograft survival in preclinical models of transplantation and in experimental models of autoimmune diseases, and is the first in a new class of drugs called sphingosine 1‐phosphate receptor (S1P‐R) modulators.

The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors*

The results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.

The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors

Observations suggest that in addition to its immunosuppressive functions, FTY720 could also have a beneficial effect in MS by direct action on OLG progenitors, and raises the question of whether MS therapies with FTY 720 should include the use of differentiation-enhancing factors such as NT-3.

FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis

Gene deletion and reverse pharmacology studies have shown that FTY720 acts at S1P1 receptors on lymphocytes and the endothelium, thereby inhibiting the egress of T- and B cells from secondary lymphoid organs into the blood and their recirculation to inflamed tissues.

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

It is shown that FTY720 localizes to the CNS white matter, preferentially along myelin sheaths, and is likely due to a culmination of mechanisms involving reduction of autoreactive T cells, neuroprotective influence of FTY 720-P in the CNS, and inhibition of inflammatory mediators in the brain.

FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.

Results indicate that FTY 720 exhibits not only a prophylactic but also a therapeutic effect on EAE in rats and mice, and that the effect of FTY720 appears to be due to a reduction of the infiltration of myelin antigen-specific CD4(+) T cells into the inflammation site.

Overview of FTY720 clinical pharmacokinetics and pharmacology.

FTY720 elicits a prompt and dose-dependent decrease in peripheral blood lymphocytes by redirecting them from the circulation to the lymph nodes without impairing lymphocyte functions, and an association among FTY720 blood concentration, decrease in lymphocyte counts, and freedom from acute rejection episodes has been observed in early clinical development trials in de novo kidney transplantation.

Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.

The generation of sphingosine kinase 2 (SPHK2) knockout mice is reported on and it is demonstrated that this enzyme is essential for FTY720 phosphate formation in vivo, indicating that SPHK2 is constantly required to maintain FTY 720 phosphate levels in vivo.